and we re manufacturing that here to deliver the genes we re delivering into the body. in addition, at meira, we ve actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells and green are the cone cells, so they exist in this kind of mosaic. early results of using gene therapy to treat retinitis pigmentosa has shown that it could potentially not only slow the progression of the disease, but in some cases reverse some of its effects.
scientists and researchers here are looking to progress it to the next level. traditional gene therapy works by replacing broken or faulty genes that are causing a condition with working copies of those genes. the therapies being developed here use harmless viruses to carry the genes, which are being paired with a form of biological switch that can be taken in tablet form. where disease is caused by a gene becoming incorrectly switched on, this treatment tries to turn it off or vice versa. when the idea of gene therapy started, one of the big issues was, how do you get those genes into people? so we, and others, over the last five to ten years have developed a new viral vector, and we re manufacturing that here to deliver the genes we re delivering into the body. in addition, at meira,
so we and others, over the last five to ten years, have developed a new viral vector, and we re manufacturing that here to deliver the genes we re delivering into the body. in addition, at meira, we ve actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes that are delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells are the cone cells, so they exist in this kind of mosaic. early results of using gene therapy to treat retinitis pigmentosa has shown that it could potentially not only slow the progression of the disease, but in some cases reverse some of its effects.
here to deliver the genes we re delivering into the body. in addition, at meira, we ve actually developed over the last seven years a totally new technology which allows us to, in the future, control how those genes that are delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells are the cone cells, so they exist in this kind of mosaic. early results of using gene therapy to treat retinitis pigmentosa has shown that it could potentially not only slow the progression of the disease, but, in some cases, reverse some of its effects. the work being done here has real
KABEER YOUSUF@kabeeryousefThe Muscat Stock Exchange (MSX) has signed a Memorandum of Understanding (MoU) with Middle East Investor Relations Association (MEIRA) and appointed a.